Search Results
You are looking at 1 - 8 of 8 items for
- Author: C. KORDON x
- Refine by access: All content x
Search for other papers by M. HERY in
Google Scholar
PubMed
Search for other papers by E. LAPLANTE in
Google Scholar
PubMed
Search for other papers by C. KORDON in
Google Scholar
PubMed
Unité de Neurobiologie (U-109) de l'I.N.S.E.R.M. 2ter, Rued'Alésia 75014, Paris, France
(Received 24 March 1975)
We have shown previously (Hery, Laplante & Kordon, 1975) that blockade of serotonin (5-HT) biosynthesis by p-chlorophenylalanine (p-CPA) specifically inhibits the circadian release of luteinizing hormone (LH) observed in ovariectomized, oestradiol-implanted rats. Since changes in plasma LH levels can often be correlated with variations in the pituitary sensitivity to luteinizing hormone releasing hormone (LH-RH) (Cooper, Fawcett & McCann, 1974), it was important to check whether 5-HT depletion was able to affect directly the response of the pituitary. In addition, since adrenal progestins have been shown to affect gonadotrophin secretion in ovariectomized animals (Lawton, 1972), and in view of the effects of p-CPA on corticotrophin release (Scapagnini, Moberg, Van Loon, De Groot & Ganong, 1971), it was also relevant to make sure that the gonadotrophin changes we described after treatment with that drug did not involve
Search for other papers by M. T. Bluet-Pajot in
Google Scholar
PubMed
Search for other papers by F. Mounier in
Google Scholar
PubMed
Search for other papers by D. Durand in
Google Scholar
PubMed
Search for other papers by C. Kordon in
Google Scholar
PubMed
ABSTRACT
The effects of dopamine on GH release were investigated both in vivo in freely moving intact rats and in rats with a mediobasal hypothalamic lesion, and in vitro in a perifusion system using dispersed male rat pituitary cells kept in primary culture. In vivo, dopamine (5 mg/kg body weight) induced a rapid and very transient increase in plasma GH levels in lesioned but not in intact rats. This increase was markedly inhibited by a prior injection of the D1 antagonist SCH 23390 (0·5 mg/kg) but not of the D2 antagonist domperidone (0·5 mg/kg). The D, agonist SKF 38393 induced a dose-dependent stimulation of GH release in lesioned rats, and the effect obtained with a dose of 5 mg/kg was abolished by pretreatment with SCH 23390 (0·5 mg/kg). In vitro, dopamine (0·1 μmol/l) and SKF 38393 (0·1 μmol/l) provoked a rapid and reversible release of GH from superfused rat pituitary cells; this effect was markedly inhibited by simultaneous superfusion of SCH 23390 (1 μmol/l). These findings indicate that dopamine can stimulate basal GH release at the pituitary level and that this stimulation is mediated by D1 but not by D2 receptors. They also support the hypothesis that unidentified hypothalamic neurohormones may modulate this effect.
Journal of Endocrinology (1990) 127, 191–196
Search for other papers by F. GOGAN in
Google Scholar
PubMed
Search for other papers by I. A. BEATTIE in
Google Scholar
PubMed
Search for other papers by M. HERY in
Google Scholar
PubMed
Search for other papers by E. LAPLANTE in
Google Scholar
PubMed
Search for other papers by C. KORDON in
Google Scholar
PubMed
SUMMARY
Implantation of oestradiol into adult rats of both sexes induced different patterns of LH secretion depending on the time at which gonadectomy or testosterone injection were performed. Castration 2 h after birth allowed an LH peak to occur daily at 18.00 h, but its amplitude was lower than that of adult gonadectomized female rats treated with oestradiol. Castration 24 h after birth elicited two kinds of response; a circadian discharge of LH lower than that of male rats gonadectomized 2 h after birth or a steady low level of LH. The LH rhythmicity induced by implantation of oestradiol was not seen after castration at 8 weeks of age. Neonatal administration of testosterone to female rats prevented the LH peak induced by oestradiol that was seen in adult ovariectomized rats. Neonatal or adult ovariectomy did not interfere with the rhythmical response of LH after implantation of oestradiol. Thus, it is concluded that sexual differentiation of the hypothalamus is primarily of masculine origin.
Search for other papers by F. GOGAN in
Google Scholar
PubMed
Search for other papers by A. SLAMA in
Google Scholar
PubMed
Search for other papers by B. BIZZINI-KOUTZNETZOVA in
Google Scholar
PubMed
Search for other papers by F. DRAY in
Google Scholar
PubMed
Search for other papers by C. KORDON in
Google Scholar
PubMed
Testosterone secretion in the male rat was high during the late fetal and immediate postnatal periods. It then showed a rapid decrease 3 h after birth and remained low until puberty.
Male rats from mothers given daily injections of an antibody to testosterone during the week before delivery displayed an LH peak when they were adult, orchidectomized and implanted with oestradiol. However, the amplitude of the peak was far smaller than in female rats from the same mothers treated in the same manner.
Thus, the critical period during which testosterone triggers hypothalamic sexual differentiation is very close to birth, possibly starting at the end of the fetal period.
Search for other papers by M. T. Bluet-Pajot in
Google Scholar
PubMed
Search for other papers by D. Durand in
Google Scholar
PubMed
Search for other papers by F. Mounier in
Google Scholar
PubMed
Search for other papers by C. Schaub in
Google Scholar
PubMed
Search for other papers by C. Kordon in
Google Scholar
PubMed
The β-adrenergic agonist, isoprenaline, and antagonist, propranolol, had no effect on the delayed basal secretion of GH consistently observed in rats treated with the narco-analgesic gamma-hydroxybutyrate. Under the same experimental conditions, GH release was distinctly stimulated by infusion of the α-adrenergic agonist, clonidine, and by morphine; both responses were dose-dependent. The effects of β-adrenergic agonists and antagonists on these GH responses were as follows: in rats pretreated with isoprenaline the GH release induced by clonidine and morphine was abolished whereas it was enhanced in rats pretreated with propranolol. These data confirmed and extended previous reports from this laboratory on the inhibitory role of β-adrenergic receptors on GH regulation.
Search for other papers by M. T. BLUET-PAJOT in
Google Scholar
PubMed
Search for other papers by C. SCHAUB in
Google Scholar
PubMed
Search for other papers by F. MOUNIER in
Google Scholar
PubMed
Search for other papers by A. SEGALEN in
Google Scholar
PubMed
Search for other papers by J. DUHAULT in
Google Scholar
PubMed
Search for other papers by C. KORDON in
Google Scholar
PubMed
The administration of gamma-hydroxybutyrate (GHB) induced a consistent secretory episode of growth hormone (GH) in the morning followed by basal levels of secretion of GH for several hours. The measurement of endogenous noradrenaline, dopamine and serotonin (5-HT) following infusion of GHB showed that dopamine concentrations were significantly increased in the striatum; at the level of the hypothalamus, however, no significant differences were observed between control and GHB-treated animals.
The data reported in this study are consistent with the interpretation that the neurotransmitter regulation of GH release and the modulation of hypothalamic gluco-receptor systems are not fundamentally different in rodents and primates.
Clonidine, an α-adrenergic agonist, enhanced the peak of GH observed in the morning and caused a rapid increment of GH during the period when it was normally at basal levels. Under the same experimental conditions, dopamine agonists, apomorphine and levodopa, had no effect on GH secretion. The inhibition of catecholamine synthesis by α-methyl-p-tyrosine blocked the secretory episode of GH following administration of GHB and after insulin hypoglycaemia whereas the GH rise induced by clonidine was unchanged. The inhibition of 5-HT synthesis by p-chlorophenylalanine also suppressed the secretory episode of GH seen in the morning and the release of GH induced by hypoglycaemia; both being partly restored in animals pretreated with 5-hydroxytryptamine.
Search for other papers by G. CHAZAL in
Google Scholar
PubMed
Search for other papers by M. FAUDON in
Google Scholar
PubMed
Search for other papers by F. GOGAN in
Google Scholar
PubMed
Search for other papers by M. HERY in
Google Scholar
PubMed
Search for other papers by C. KORDON in
Google Scholar
PubMed
Search for other papers by E. LAPLANTE in
Google Scholar
PubMed
Implantation of a solid source of oestradiol into ovariectomized rats produced constant plasma concentrations of the hormone over a long period of time. Under these conditions, LH is released in a circadian pattern with a very marked peak in the afternoon. This circadian rhythm is synchronized to the light–darkness cycle, since it follows exactly a shift in the nycthemeral cycle. The first peak appeared on day 3 after placement of the oestrogen implant; its amplitude was constant from days 3 to 9 after implantation, and decreased gradually during prolonged implantation. The afternoon peak was not correlated with changes in the pituitary sensitivity to exogenous LH releasing hormone (LH-RH), since the LH response to increasing doses of the peptide could be superimposed in the morning and in the afternoon. However, the decreased amplitude of the rhythm observed after more than 9 days of implantation seemed to depend upon a progressive desensitization of the pituitary gland to LH-RH. Pituitary LH content also decreased as a function of implantation time. It is concluded that, under conditions of constant plasma oestradiol concentrations and of constant pituitary sensitivity to LH-RH, a daily activation of the neural trigger releasing pituitary gonadotrophins occurs.
Search for other papers by F Mounier in
Google Scholar
PubMed
Search for other papers by E Pellegrini in
Google Scholar
PubMed
Search for other papers by C Kordon in
Google Scholar
PubMed
Search for other papers by J Epelbaum in
Google Scholar
PubMed
Search for other papers by M T Bluet-Pajot in
Google Scholar
PubMed
Involvement of endogenous corticotropin releasing hormone (CRH) in the regulation of spontaneous growth hormone (GH) secretion was investigated. A CRH antagonist, α helical CRH 9–41, was intracerebroventricularly infused for 36 h at a rate of 1 μg/0·5 μl/h to freely moving, cannulated adult male rats. Serial blood samples were drawn every 20 min for the last 8 hours of α helical CRH 9–41 infusion. The treatment induced a marked increase in GH peak amplitude without affecting either trough levels or numbers of peaks. In parallel, levels of growth hormone releasing hormone (GHRH) mRNA in the arcuate nucleus, but not of somatotropin release inhibiting hormone (SRIH) mRNA in the periventricular and arcuate nuclei, were increased. These data suggest that, in addition to its action in the stress-induced inhibition of GH secretion through regulation of periventricular SRIH neurons, CRH can also act as a modulator of endogenous GH secretion through regulation of arcuate GHRH neurons. Whether the modulatory effects of CRH on GHRH neurons are direct or indirect remains to be established.
Journal of Endocrinology (1997) 152, 431–436
